BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 22554854)

  • 1. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.
    Ishikawa N; Hattori N; Yokoyama A; Kohno N
    Respir Investig; 2012 Mar; 50(1):3-13. PubMed ID: 22554854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome.
    Remuzgo-Martínez S; Atienza-Mateo B; Ocejo-Vinyals JG; Genre F; Pulito-Cueto V; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Pérez-Fernández R; Prieto-Peña D; Irure J; Romero-Bueno F; Sanchez-Pernaute O; Alonso-Moralejo R; Nuño L; Bonilla G; Vicente-Rabaneda EF; Grafia I; Prieto-González S; Narvaez J; Trallero-Araguas E; Selva-O'Callaghan A; ; ; Gualillo O; Cavagna L; Cifrián JM; Renzoni EA; Castañeda S; López-Mejías R; González-Gay MA
    Sci Rep; 2021 Nov; 11(1):22574. PubMed ID: 34799647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].
    Yu JF; Jin YB; He J; An Y; Li ZG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):910-914. PubMed ID: 29045979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
    d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
    Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis.
    Kohno N
    J Med Invest; 1999 Aug; 46(3-4):151-8. PubMed ID: 10687309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
    Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
    Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
    Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
    Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study.
    Oguz EO; Kucuksahin O; Turgay M; Yildizgoren MT; Ates A; Demir N; Kumbasar OO; Kinikli G; Duzgun N
    Clin Rheumatol; 2016 Mar; 35(3):663-6. PubMed ID: 26758437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
    Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
    Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interstitial lung disease and lung cancer].
    Ishikawa N; Kohno N
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):6-9. PubMed ID: 20087026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
    Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
    Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could KL-6 levels in COVID-19 help to predict lung disease?
    Frix AN; Schoneveld L; Ladang A; Henket M; Duysinx B; Vaillant F; Misset B; Moutschen M; Louis R; Cavalier E; Guiot J
    Respir Res; 2020 Nov; 21(1):309. PubMed ID: 33234132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis.
    Mostafa AI; Salem AE; Ahmed HAM; Bayoumi AI; Halim RMA; Samie RMA
    Tuberc Respir Dis (Seoul); 2021 Jul; 84(3):200-208. PubMed ID: 33840176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
    Ma H; Lu J; Song Y; Wang H; Yin S
    BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.
    Hamada T; Samukawa T; Kumamoto T; Hatanaka K; Tsukuya G; Yamamoto M; Machida K; Watanabe M; Mizuno K; Higashimoto I; Inoue Y; Inoue H
    BMC Pulm Med; 2015 Sep; 15():110. PubMed ID: 26424433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
    Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels.
    Horimasu Y; Hattori N; Ishikawa N; Kawase S; Tanaka S; Yoshioka K; Yokoyama A; Kohno N; Bonella F; Guzman J; Ohshimo S; Costabel U
    Respir Med; 2012 Dec; 106(12):1756-64. PubMed ID: 22995277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
    Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
    Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression.
    Stock CJW; Hoyles RK; Daccord C; Kokosi M; Visca D; De Lauretis A; Alfieri V; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Chua F; Maher TM; Abraham DJ; Ong V; Donovan J; Sestini P; Denton CP; Wells AU; Renzoni EA
    Respirology; 2021 May; 26(5):461-468. PubMed ID: 33336433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.